FDA Grants Priority Review to BridgeBio’s Oral Infigratinib for Pediatric Achondroplasia
FDA grants priority review to BridgeBio's oral infigratinib for pediatric achondroplasia, offering a once-daily pill alternative to injections.
Adaptive Clinical Trial Design Adaptive Trial Design AI Drug Discovery AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Artificial Intelligence in Clinical Trials Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies DOGE FDA Budget Cuts dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
FDA grants priority review to BridgeBio's oral infigratinib for pediatric achondroplasia, offering a once-daily pill alternative to injections.
From a cancer patient's self-built AI agent to ARPA-H's phaseless trial model, AI has crossed from analytics into operations....
When scan sets split into separate rows, MCAs lose the parent schedule. Here is what that costs you and...
Newron's investigators assessed three of four evenamide deaths as unrelated. The FDA, looking at the same events pooled across...
TRIUMPH-2's Phase 3 data on retatrutide in 1,152 T2D patients challenges every assumption sponsors hold about GLP-1 trial design...
eClinical Solutions hosts ENGAGE 2026 with 250+ attendees exploring clinical data management solutions for FDA compliance and trial operations.
WCG's Activation Intelligence cuts study activation time by 20 hours per trial by reconciling conflicting information across protocols and...
GCCL and LabConnect sign MOU to streamline cross-regional clinical trial support across North America and Asia-Pacific laboratories.
AKIR001 radiopharmaceutical shows no dose-limiting toxicities in eight patients, with imaging confirming selective tumor targeting in first-in-human trial.
ArkBio receives FDA clearance for AK0406, a drug-Fc conjugate designed to prevent influenza in adults during the upcoming U.S....